CL2018003502A1 - Métodos para tratar la osificación heterotópica. - Google Patents

Métodos para tratar la osificación heterotópica.

Info

Publication number
CL2018003502A1
CL2018003502A1 CL2018003502A CL2018003502A CL2018003502A1 CL 2018003502 A1 CL2018003502 A1 CL 2018003502A1 CL 2018003502 A CL2018003502 A CL 2018003502A CL 2018003502 A CL2018003502 A CL 2018003502A CL 2018003502 A1 CL2018003502 A1 CL 2018003502A1
Authority
CL
Chile
Prior art keywords
methods
reduce
heterotopic ossification
treat
treat heterotopic
Prior art date
Application number
CL2018003502A
Other languages
English (en)
Inventor
Clarissa Desjardins
Donna Roy Grogan
Jeffrey Neal Packman
Mark Harnett
Original Assignee
Clementia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clementia Pharmaceuticals Inc filed Critical Clementia Pharmaceuticals Inc
Publication of CL2018003502A1 publication Critical patent/CL2018003502A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCIÓN PRESENTA REGÍMENES DE DOSIFICACIÓN Y FORMULACIONES FARMACÉUTICAS PARA LA ADMINISTRACIÓN ORAL DE PALOVAROTENO. LOS REGÍMENES DE DOSIFICACIÓN PUEDEN REDUCIR LA OSIFICACIÓN HETEROTÓPICA, REDUCIR EL NÚMERO DE BROTES Y/O REDUCIR LA GRAVEDAD DE LOS BROTES EN SUJETOS QUE SUFREN DE FIBRODISPLASIA OSIFICANTE PROGRESIVA.
CL2018003502A 2016-06-08 2018-12-06 Métodos para tratar la osificación heterotópica. CL2018003502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662347381P 2016-06-08 2016-06-08

Publications (1)

Publication Number Publication Date
CL2018003502A1 true CL2018003502A1 (es) 2019-04-26

Family

ID=60578331

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003502A CL2018003502A1 (es) 2016-06-08 2018-12-06 Métodos para tratar la osificación heterotópica.

Country Status (18)

Country Link
US (6) US10864194B2 (es)
EP (2) EP4249490A3 (es)
JP (2) JP7023868B2 (es)
KR (1) KR102486607B1 (es)
CN (2) CN120204216A (es)
AU (2) AU2017276835B2 (es)
BR (1) BR112018075422A2 (es)
CA (1) CA3025854A1 (es)
CL (1) CL2018003502A1 (es)
EA (1) EA201892497A1 (es)
ES (1) ES2963348T3 (es)
IL (3) IL263440B (es)
MX (2) MX390115B (es)
MY (1) MY200642A (es)
PH (1) PH12018502563A1 (es)
SG (1) SG11201810658PA (es)
WO (1) WO2017210792A1 (es)
ZA (1) ZA201808102B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2613776T3 (pl) 2010-09-01 2021-01-11 Thomas Jefferson University Kompozycja oraz sposób naprawy i regeneracji mięśni
ES2963348T3 (es) * 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
BR112019009929A2 (pt) 2016-11-16 2019-08-20 Clementia Pharmaceuticals Inc métodos para inibir a formação de um osteocondroma, para reduzir o tamanho de um osteocondroma, para desacelerar o crescimento de um osteocondroma e para reduzir hiperplasia de cartilagem
WO2020118405A1 (en) * 2018-12-13 2020-06-18 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
US12569468B2 (en) 2020-06-11 2026-03-10 Yang Sheng Tang Company, Ltd. Use of palovarotene in treatment against HBV virus
EP4470537A1 (en) * 2023-05-30 2024-12-04 Queen's University At Kingston Compound for use in treating fibrodysplasia ossificans progressiva (fop)
EP4470536A1 (en) * 2023-05-30 2024-12-04 Queen's University At Kingston Compound for use in treating fibrodysplasia ossificans progressiva (fop)
CN119185298B (zh) * 2024-10-30 2025-09-26 武汉大学人民医院（湖北省人民医院） 帕罗伐汀在制备用于治疗脑出血后急性脑损伤的药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
AU784377B2 (en) 2000-03-14 2006-03-23 Arthur V. Sampaio Compositions and methods for affecting osteogenesis
JP4118675B2 (ja) 2000-10-02 2008-07-16 エフ．ホフマン−ラ ロシュ アーゲー 気腫治療用新規レチノイド
PL209697B1 (pl) 2001-09-18 2011-10-31 Hoffmann La Roche Pochodne mocznika, środek farmaceutyczny i zastosowanie pochodnych mocznika
AU2002329276B2 (en) 2001-09-18 2008-04-24 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists I
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
AU2006227623B2 (en) 2005-03-17 2011-10-20 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
EP1938815A1 (en) 2005-09-27 2008-07-02 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability
US20070213308A1 (en) 2006-01-26 2007-09-13 Lessem Jan N Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
WO2007113122A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
DK2026778T3 (en) 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
CA2667706A1 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
JP2009235031A (ja) 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
US8969350B2 (en) 2008-12-18 2015-03-03 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
EP2393915A4 (en) 2009-02-05 2012-12-26 Regenertech Pty Ltd PROCESS FOR THE PREPARATION OF PRECURSOR CELLS FROM DIFFERENTIATED CELLS
WO2011011513A1 (en) * 2009-07-21 2011-01-27 University Of Washington Through Its Center For Commercialization Inhibition of pathological bone formation
PL2613776T3 (pl) 2010-09-01 2021-01-11 Thomas Jefferson University Kompozycja oraz sposób naprawy i regeneracji mięśni
WO2012047674A2 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013006372A1 (en) * 2011-07-01 2013-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating pathologic heterotopic ossification
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
EP2817292B1 (en) * 2012-02-22 2019-12-18 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
EP2900238B1 (en) 2012-09-28 2017-12-06 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
CN109589324B (zh) 2012-11-08 2022-06-14 国立大学法人山口大学 角结膜病症的治疗剂
US20160115167A1 (en) * 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
CN105377258B (zh) 2013-05-22 2020-08-28 国立大学法人山口大学 视网膜脉络膜病症的抑制剂
JP2017536411A (ja) * 2014-10-01 2017-12-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
WO2017070194A1 (en) 2015-10-19 2017-04-27 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
WO2017112431A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of Michigan Method of treating heterotopic ossification
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
WO2020118405A1 (en) 2018-12-13 2020-06-18 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification

Also Published As

Publication number Publication date
SG11201810658PA (en) 2018-12-28
WO2017210792A1 (en) 2017-12-14
EP4249490A3 (en) 2023-12-13
IL295440A (en) 2022-10-01
ES2963348T3 (es) 2024-03-26
US12201614B2 (en) 2025-01-21
US20240277667A1 (en) 2024-08-22
EP4249490A2 (en) 2023-09-27
EP3468554A4 (en) 2020-01-22
AU2017276835A1 (en) 2018-12-13
AU2022202148B2 (en) 2023-08-24
EP3468554C0 (en) 2023-08-09
PH12018502563A1 (en) 2019-10-14
JP2019517528A (ja) 2019-06-24
MX390115B (es) 2025-03-20
EP3468554A1 (en) 2019-04-17
US20260021073A1 (en) 2026-01-22
AU2022202148A1 (en) 2022-04-21
US12138245B2 (en) 2024-11-12
BR112018075422A2 (pt) 2019-03-12
AU2017276835B2 (en) 2022-03-31
CA3025854A1 (en) 2017-12-14
US10864194B2 (en) 2020-12-15
KR102486607B1 (ko) 2023-01-11
US20230285360A1 (en) 2023-09-14
IL263440B (en) 2022-09-01
JP7023868B2 (ja) 2022-02-22
IL295440B1 (en) 2025-01-01
US12458626B2 (en) 2025-11-04
US20190216781A1 (en) 2019-07-18
CN109562099A (zh) 2019-04-02
ZA201808102B (en) 2024-04-24
CN120204216A (zh) 2025-06-27
JP2022019995A (ja) 2022-01-27
US11622959B2 (en) 2023-04-11
EP3468554B1 (en) 2023-08-09
IL317726A (en) 2025-02-01
MY200642A (en) 2024-01-08
US20210069152A1 (en) 2021-03-11
IL295440B2 (en) 2025-05-01
KR20190017883A (ko) 2019-02-20
EA201892497A1 (ru) 2019-05-31
US20240350457A1 (en) 2024-10-24
NZ748939A (en) 2025-03-28
MX2022001991A (es) 2022-03-11
IL263440A (en) 2019-01-31
MX2018015108A (es) 2019-08-29

Similar Documents

Publication Publication Date Title
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
IL264210A (en) High-strength oral cannabinoid dosage forms
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
JOP20220020B1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
SV2017005601A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
MX2022001991A (es) Metodos para tratar la osificacion heterotopica.
BR112017023674A2 (pt) suspensões farmacêuticas contendo partículas de fármaco, dispositivos para sua administração, e métodos de seu uso
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
EP3526195A4 (en) SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE
KR102228571B9 (ko) 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
DK3773595T3 (da) Farmaceutiske anticancer-sammensætninger til kombineret terapi
CO2019002245A2 (es) Combinación de agonistas de fxr
MX2017009164A (es) Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
EA201990399A1 (ru) Соединения, композиции и их применение
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112017004552A2 (pt) composições farmacêuticas
MA40645A (fr) Préparation prébiotique à base d'inuline